Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Top Cited Papers
- 2 May 2020
- journal article
- review article
- Published by Elsevier BV in Autoimmunity Reviews
- Vol. 19 (7), 102568
- https://doi.org/10.1016/j.autrev.2020.102568
Abstract
No abstract availableFunding Information
- Central Laboratory at ASST Spedali Civili of Brescia
- Department of Laboratory Diagnostics
This publication has 19 references indexed in Scilit:
- Laboratory abnormalities in patients with COVID-2019 infectioncclm, 2020
- Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trialThe Lancet Respiratory Medicine, 2020
- Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in SepsisFrontiers in Immunology, 2019
- Eosinophils from Physiology to Disease: A Comprehensive ReviewBioMed Research International, 2018
- Is secondary hemophagocytic lymphohistiocytosis behind the high fatality rate in Middle East respiratory syndrome corona virus?Journal of Applied Hematology, 2015
- Adult haemophagocytic syndromeThe Lancet, 2014
- Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatmentJournal of General Virology, 2013
- The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndromeBMC Medicine, 2013
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman diseaseBlood, 2008
- Clinical research in critically ill patients: the situation in ItalyIntensive Care Medicine, 2008